Jonathan Choy, PhD
Study: Immune regulation by IL-6 in Giant cell arteritis Institution: Simon Fraser University, Burnaby, British Columbia Canada Award: $50,000, one-year grant Summary: Giant cell arteritis (GCA) is vascular disease that is characterized by thickening of the artery wall, resulting in a block in blood flow. It most often affects the temporal…...
Susan Jick, DSc
Study: Longitudinal study of morbidity and mortality in vasculitis patients Institution: Boston Collaborative Drug Surveillance Program, Boston University School of Public Health, Boston, Massachusetts Award: $98,641, two-year study Summary: Vasculitis is an inflammation of blood vessels which is mistakenly thought to be an attack by the immune system. It can affect…...
Renate Kain, MD, PhD
Study: Role of LAMP-2 in tolerance to ANCA antigens Institution: Medical University of Vienna, Vienna, Austria Award: $50,000, one-year study Summary: Despite recent advances in treatment, ANCA-associated vasculitis (AAV) still causes serious morbidity especially after the acute injury has been controlled, emphasizing the need for better ways to monitor disease activity and…...
Davide Martorana, PhD
Study: Exome Sequencing in EGPA Patients Institution: Diagnostic Department, Medical Genetics Unit, University Hospital of Parma, Parma, Italy Award: $48,000, two-year study Summary: Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystem disorder, belonging to the small vessel anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). EGPA is defined as an eosinophil-rich and granulomatous inflammation…...
Parameswaran Nair, MD, PhD, FRCP, FRCPC
Study: Investigating Autoimmune Mechanisms Underlying EGPA Institution: McMaster University in Ontario, Canada (co- investigators Manali Mukjerhee MD and Nader Khaladi) Award: $50,000, one-year study Summary: In many diseases, our own body produces antibodies directed against our own tissues and organs (autoantibodies), a phenomenon called autoimmunity. EGPA/Churg Strauss Syndrome is a serious rare…...
Connect with us on social media!
Participate in Research
